Status:
COMPLETED
BLI1100-202: BLI1100 for the Treatment of Moderate to Severe Acne Vulgaris
Lead Sponsor:
Braintree Laboratories
Conditions:
Acne Vulgaris
Eligibility:
All Genders
12-45 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to compare the safety and efficacy of BLI1100 formulations to placebo for the treatment of moderate to severe acne vulgaris.
Eligibility Criteria
Inclusion
- Males or females 12 to 45 years of age with facial acne vulgaris
- Qualifying Investigator's Global Assessment severity score
- Qualifying number of non-inflammatory lesions
- Qualifying number of inflammatory lesions
Exclusion
- Facial hair (beard), excessive scarring, sunburn or other disfigurement that may obscure the accurate assessment of acne grade
- Using medications that are reported to exacerbate acne
- Any clinically relevant finding at their baseline physical examination or dermatological medical history such as severe systemic diseases or diseases of the facial skin
- Have a known hypersensitivity or previous allergic reaction to any of the components
- Patients who have participated in an investigational clinical, surgical, drug, or device study within the past 30 days
- Patients who, in the opinion of the investigator, should not be included in the study for any reason, including inability to follow study procedures
Key Trial Info
Start Date :
February 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
369 Patients enrolled
Trial Details
Trial ID
NCT01815450
Start Date
February 1 2013
Last Update
February 2 2015
Active Locations (15)
Enter a location and click search to find clinical trials sorted by distance.
1
Center for Dermatology Clincal Research
Fremont, California, United States, 94538
2
North Florida Dermatology Associates
Jacksonville, Florida, United States, 32204
3
Ameriderm Research
Ormond Beach, Florida, United States, 32174
4
Peachtree Dermatology Associates Research Center
Atlanta, Georgia, United States, 30327